Mizuho raised the firm’s price target on Wave Life Sciences (WVE) to $22 from $19 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. The firm says Wave Life remains a potential secular growth story for 2025.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE: